Latest treatment of migraine Stories
CAMBIA® (Diclofenac Potassium for Oral Solution) is elevated to Level A, based on rigorous clinical data demonstrating its effectiveness for acute migraine attacks, consistent with other therapies
DURHAM, N.C., Jan. 13, 2015 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., today announced that it has completed a $37.1 million Series C preferred stock offering.
AVP-825 relies on novel closed palate Breath Powered(TM) drug delivery technology YARDLEY, Pa., March 27, 2014 /PRNewswire/ -- The U.S.
ALISO VIEJO, Calif., March 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S.
ALISO VIEJO, Calif., Jan. 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has submitted a New Drug Application (NDA) to the U.S.
New Guidelines Support Use by Migraine Specialists in the UK SUNNYVALE, Calif., Jan.
SAN MATEO, Calif., Jan.
- Large; stout; burly.